Nilotinib associated with stable outcomes in Ph+CML

Cowles, Carey; Fisher, Stacey L.; Harris, Jason
December 2010
Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p30
The article discusses the association of nilotinib, an inhibitor for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), with stable outcomes.


Related Articles

  • Nilotinib showed continued efficacy in patients with CML.  // Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p18 

    The article reports on a study which revealed the continued efficacy of nilotinib in patients with chronic myelogenous leukemia (CML).

  • Ponatinib: Another new treatment for CML. Lohr, Lisa K. // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p41 

    The article reports that three agents including bosutinib and omacetaxine was approved by the U.S. Food and Drug Administration (FDA) for use in patients with chronic myeloid leukemia.

  • Dasatinib.  // Reactions Weekly;03/23/2013, Issue 1445, p18 

    The article presents case studies of five patients who were diagnosed with chronic myeloid leukaemia (CML) and developed transient grade 3 or 4 toxicities during treatment with dasatinib.

  • Price of cancer drugs unsustainable.  // PharmacoEconomics & Outcomes News;05/11/2013, Issue 678, p1 

    The article focuses on the consensus among Chronic Myeloid Leukemia (CML) experts that the price of drugs used to treat the disease in 2013 are too high, unsustainable and are harmful to the sustainability of the U.S. national healthcare systems.

  • FDA approves nilotinib for newly diagnosed chronic phase Ph+CML.  // Hem/Onc Today;7/10/2010, Vol. 10 Issue 13, p1 

    The article reports on the approval of a new indication for the BCR-ABL inhibitor nilotinib by the U.S. Food and Drug Administration (FDA) for treatment of Philadelphia chromosome positive chronic myeloid leukemia.

  • Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. Abdullah Altintas; Timucin Cil; Ilhan Kilinc; Muhammet Kaplan; Orhan Ayyildiz // Journal of Neuro-Oncology;Aug2007, Vol. 84 Issue 1, p103 

    Summary  Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of...

  • Nilotinib rapidly produced a high response rate for Philadelphia chromosome-positive CML.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p54 

    The article discusses research on the positive cytogenetic response rate and major molecular response rate in patients with Philadelphia chromosome-positive chronic myeloid leukemia treated with nilotinib for a year, conducted by G. Rosti et al, published in a a 2009 issue of the journal "Blood."

  • Nilotinib linked to fewer BCR-ABL mutations in chronic phase CML. Adams, Stacey L.; Leiser, Mark; Shafer, Emily; Taliercio, Adam; Volansky, Rob // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p44 

    The article discusses the results of a study which showed a link between nilotinib and fewer treatment-emergent breakpoint cluster region-abelson (BCR-ABL) mutations than imatinib in chronic myeloid leukemia treatment and reduced rates of progression to accelerated phase.

  • Nilotinib.  // Reactions Weekly;Mar2014, Vol. 1490 Issue 1, p28 

    The article presents a case report of a 66-year-old man who developed pleural effusions, fatigue and muscle cramps during treatment with nilotinib for chronic myeloid leukaemia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics